graft-versus-host disease


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to graft-versus-host disease: cGVHD

graft-ver·sus-host disease

(grăft′vûr′səs-hōst′, -səz-)
n.
A condition in which cells from the transplanted tissue of a donor initiate an immunologic attack on the cells and tissue of the recipient.

graft′-ver`sus-host′ disease`


n.
a reaction in which the cells of transplanted tissue immunologically attack the cells of the host.
Mentioned in ?
References in periodicals archive ?
Enlivex has completed a phase IIa clinical trial to prevent graft-versus-host disease in a matched donor population.
In univariable models, the researchers found that prior chronic lymphocytic leukemia (CLL) (hazard ratio, 2.2), chronic graft-versus-host disease (GVHD) (HR, 3.1), and age at transplant of more than 60 years (HR, 10.8) were all linked to an increased risk for squamous cell carcinomas.
The US Food and Drug Administration (FDA) has extended the review period for United States-based Incyte's supplemental new drug application (NDA) for acute graft-versus-host disease (GVHD) treatment, Jakafi (ruxolitinib), it was reported on Friday.
Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is a common complication of hematopoietic stem cell transplant (HSCT) and is associated with significant morbidity and mortality.
'Bone marrow transplants from partially matched donors carry about an 80 percent risk of graft-versus-host disease and the myxoma treatment would address that,' Cogle added.
MELBOURNE, Australia, May 24, 2018 -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) announced that the final patient was treated in Cohort B of its Phase 1 clinical trial of CYP-001, its Cymerus mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD).
MELBOURNE, Australia, May 24, 2018 --Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) announced that the final patient was treated in Cohort B of its Phase 1 clinical trial of CYP-001, its Cymerus mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD).
Bscheider et al., "Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease," Blood, vol.
Graft-versus-host disease (GVHD), an immune-mediated disease caused by complex interactions between donor and recipient immune systems, is a leading cause of morbidity and mortality following HSCT [4, 6, 7].
Fisher et al., "A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment," Blood, vol.
Graft-versus-host disease is a complication of bone marrow transplants that can cause problems including skin rash, shortness of breath, abdominal pain, jaundice and muscle weakness.